Jennifer Lorvick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Lorvick has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Brian R. Edlin
Institute for Infectious Disease Research, National Development and Research Institutes, New York, New York, United States of America
2 shared publications A H Kral
1 shared publicationAlan R. Lifson
University of California
1 shared publicationAlex H. Kral
University of California
1 shared publicationJohn K. Watters
Minnesota Department of Health
1 shared publicationK Seal
1 shared publication
Latest Publications
- 1 January 2001
- Published by American Public Health Association in American Journal of Public Health
- Vol. 91 (1) , 46-47
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif
- 1 January 2001
- Published by American Public Health Association in American Journal of Public Health
- Vol. 91 (1) , 46-47
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif
- Open Access
- 1 December 1999
- Published by Springer Nature in Journal of Urban Health
- Vol. 76 (4) , 461-467
Incentives and accessibility: A pilot study to promote adherence to TB prophylaxis in a high-risk community
A community-based directly observed preventive therapy (DOPT) program for treatment of latent tuberculosis infection among injection drug users (IDUs) in an innercity neighborhood. To test adherence to a 6-month course of DOPT using cash incentives and an easily accessible neighborhood location. Street-recruited IDUs (N=205) were screened forMycobacterium tuberculosis (TB) infection using the Mantoux test and two controls. Subjects who had a purified protein derivative (PPD) reaction of ≥5 mm, were anergic, or had a history of a positive PPD received clinical evaluation at a community field site, provided in collaboration with the San Francisco Department of Public Health Tuberculosis Clinic. Twenty-eight subjects were considered appropriate candidates for prophylaxis with isoniazid, and 27 enrolled in the pilot study. Participants received twice-weekly DOPT at a community satellite office, with a $10 cash incentive at each visit. The 6-month (26-week) regimen was completed by 24/27 (89%) participants. The median time to treatment completion was 27 weeks (range 26 to 34 weeks). The median proportion of dosing days attended in 6 months was 96%. Community-based DOPT using cash incentives resulted in high levels of adherence and treatment completion among drug users.
- 1 December 1999
- Published by Springer Nature in Journal of Urban Health
- Vol. 76 (4) , 461-467
Open AccessIncentives and accessibility: A pilot study to promote adherence to TB prophylaxis in a high-risk community
A community-based directly observed preventive therapy (DOPT) program for treatment of latent tuberculosis infection among injection drug users (IDUs) in an innercity neighborhood. To test adherence to a 6-month course of DOPT using cash incentives and an easily accessible neighborhood location. Street-recruited IDUs (N=205) were screened forMycobacterium tuberculosis (TB) infection using the Mantoux test and two controls. Subjects who had a purified protein derivative (PPD) reaction of ≥5 mm, were anergic, or had a history of a positive PPD received clinical evaluation at a community field site, provided in collaboration with the San Francisco Department of Public Health Tuberculosis Clinic. Twenty-eight subjects were considered appropriate candidates for prophylaxis with isoniazid, and 27 enrolled in the pilot study. Participants received twice-weekly DOPT at a community satellite office, with a $10 cash incentive at each visit. The 6-month (26-week) regimen was completed by 24/27 (89%) participants. The median time to treatment completion was 27 weeks (range 26 to 34 weeks). The median proportion of dosing days attended in 6 months was 96%. Community-based DOPT using cash incentives resulted in high levels of adherence and treatment completion among drug users.